🔴 Capricor Therapeutics is trading 5% down with no clear company-specific catalyst

Capricor Therapeutics is trading at $8.46, down 5.16%, with no fresh company-specific announcement identified to explain the November 5 decline.

• The company’s latest listed release schedules third-quarter results for November 10.
• Recent reports described an earlier rally after 28 HOPE-3 investigators urged FDA approval; that prior positive news does not explain the decline.
• The supplied sector context shows biotech higher, so sector weakness does not appear to explain the move.